Efficacy of arbidol in COVID-19 patients: A retrospective study

Table 1 Comparison of recovery time of various indicators between arbidol therapy group and non–antiviral treatment control group

	Arbidol treatment (n = 72)	None-antiviral treatment (n = 60)	P value	Difference (d)
Disease duration (d)1	23.42 ± 6.92	29.60 ± 6.49	< 0.001	6.183
Days before 2 NAT negative results1	21.61 ± 6.95	27.59 ± 6.39	< 0.001	5.983
Days before significantly improved chest CT outcome1	18.33 ± 5.94	24.28 ± 5.35	< 0.001	5.949

¹t test. NAT: Nucleic acid testing; CT: Computed tomography.